TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Recipharm Pharmaceutical Development AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
10,821
|
8,398
|
9,798 |
| Financial expenses |
262
|
145
|
30 |
| Earnings before taxes |
879
|
-724
|
-629 |
| EBITDA |
1,225
|
-409
|
-254 |
| Total assets |
5,930
|
4,405
|
6,198 |
| Current assets |
4,489
|
2,778
|
4,595 |
| Current liabilities |
2,950
|
1,988
|
2,928 |
| Equity capital |
2,980
|
2,416
|
3,270 |
| - share capital |
5
|
4
|
5 |
| Employees (average) |
69
|
62
|
64 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
50.3%
|
54.8%
|
52.8% |
| Turnover per employee |
157
|
135
|
153 |
| Profit as a percentage of turnover |
8.1%
|
-8.6%
|
-6.4% |
| Return on assets (ROA) |
19.2%
|
-13.1%
|
-9.7% |
| Current ratio |
152.2%
|
139.7%
|
156.9% |
| Return on equity (ROE) |
29.5%
|
-30.0%
|
-19.2% |
| Change turnover |
2,398
|
-606
|
-354 |
| Change turnover % |
28%
|
-7%
|
-3% |
| Chg. No. of employees |
7
|
-2
|
3 |
| Chg. No. of employees % |
11%
|
-3%
|
5% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.